On October 25, 2021 Phyton Biotech reported that it will attend CPhI Worldwide 2021, both virtually and in-person to exhibit its capabilities and the wide range of applications for the company’s specialty fermentation solutions (Press release, Phyton Biotech, OCT 25, 2021, View Source [SID1234591934]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CPhI Worldwide is the largest pharmaceutical industry trade show, bringing together pharmaceutical industry suppliers and buyers from all over the world. This year, the conference is being held virtually and in-person in Milan, offering interested attendees two options to participate. The online portion of the conference will run from October 25-November 19 and the in-person portion will run from November 9-11.

Phyton Biotech has participated in the CPhI conference for over twelve years, and this year has put significant effort into showcasing its capabilities around specialty fermentation solutions and its broad application to pharmaceuticals, food ingredients, cosmetics, and traditional Chinese herbal medicines. This year, Phyton Biotech will be offering interested parties the opportunity to meet with its representatives in-person at the conference or in a virtual setting by visiting the online booth.

If you’re interested in visiting with representatives of Phyton Biotech in Milan, please email Jackie Labbe, VP Sales and Marketing, at [email protected] or Ron Chan, Business Development Manager, at [email protected].

Click here to visit Phyton Biotech’s booth at CPhI Online.

On October 25, 2021 Mevion Medical Systems reported that it has signed a contract with Kansas City Urology Care (KCUC) for the purchase of a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning technology (Press release, Mevion Medical Systems, OCT 25, 2021, View Source [SID1234591932]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proton therapy is a precise form of radiation therapy that can reduce the amount of unnecessary radiation exposure to healthy tissue, which has the potential to reduce side effects, escalate dose, and lessen the risk of secondary malignancies. HYPERSCAN technology utilizes a unique combination of optimum spot sizes, hyper-fast layer switching and a novel multi-layer proton MLC. This powerful trio provides faster and more precise dose delivery and minimizes sensitivity to motion, allowing clinicians to deliver a full field of therapeutic radiation in a single breath-hold.

The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy. By reducing the size and complexity of a proton therapy system, Mevion has overcome the practical challenges of other technologies, and created a much more compact, affordable solution. Today, new proton therapy centers in the US are almost exclusively compact single-room systems and Mevion is the preferred compact provider in the US.

"Mevion has taken the lead and has democratized proton therapy to the point where centers of all sizes can participate in the incredible benefits proton therapy can provide to their patients," said Tina Yu, CEO of Mevion. "We are very excited to partner with KCUC to bring this technology to the patients of Kansas City."

Kansas City Urology Care is the premier center for urology care in Kansas City that assures cutting-edge treatment solutions for all forms of urological conditions. For more, information about Kansas City Urology Care, please visit, www.KCUC.com.

2021 ASTRO Annual Meeting

Mevion will attend the American Society of Radiation Oncology (ASTRO) 2021 Annual Meeting from October 24th-26th. After 2020’s virtual-only event, ASTRO 2021 returns live at McCormick Place in West Chicago, where Mevion will highlight its recent updates, including a FLASH Therapy* research kit, that is expected to be made available to users in 2022, to help empower research centers of all sizes to study the potential benefits of FLASH. Mevion also invite attendees to experience the speed and precision of HYPERSCAN with RayStation 11A and learn more about our 24/7 clinical availability and the fastest installation time in the industry at booth #601.

*FLASH Therapy is currently under preclinical research and is not yet available for commercial sale or clinical use.

On October 25, 2021 CANbridge Pharmaceuticals, Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, reported that it has entered into a research collaboration and license agreement with Scriptr Global, Inc., for the development of a gene therapy treatment targeting dystrophinopathies (Press release, CANbridge Life Sciences, OCT 25, 2021, View Source [SID1234591931]). CANbridge will gain exclusive worldwide rights to develop, manufacture and commercialize a gene therapy candidate for the treatment of dystrophinopathies, using Scriptr Global’s Stitchr platform, a proprietary ribozyme-mediated RNA assembly technology. Scriptr Global will be responsible for research, while CANbridge will assume all responsibilities for development, manufacturing, regulatory, and commercialization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financial terms of the agreement include an upfront payment, development and sales payments, upon hitting certain milestones, as well as royalties based on net sales.

"We are pleased to be aligning with Scriptr Global and the Stitchr technology platform, which we believe has the potential to revolutionize the dystrophinopathy gene therapy field," said James Xue, Ph.D., Founder, Chairman and CEO of CANbridge Pharmaceuticals, Inc.

"The need for a transformative therapeutic approach for those individuals and families impacted with dystrophinopathies is great. Scriptr Global is delighted to undertake this important work with CANbridge utilizing Scriptr Global’s novel platform technology," stated Keith Alkek, Co-Founder Chairman and CEO of Scriptr Global, Inc.

About dystrophinopathies

Dystrophinopathies are X-linked genetic muscular diseases which include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and DMD-associated dilated cardiomyopathy (DCM). DMD usually presents in early childhood and is characterized by rapidly progressive muscle degeneration and weakness, leading to loss of ambulation by about 12 years of age. BMD is characterized by later-onset skeletal muscle weakness. Cardiomyopathy is a common cause of morbidity and death in both DMD and BMD patients. DCM is characterized by left ventricular dilation and congestive heart failure, usually with no clinical evidence of skeletal, or voluntary muscle involvement. The incidence of DMD is estimated to be 1/3,500 – 1/5,000 male births worldwide and 1/4,560 in China. The incidence of BMD is estimated to be 1/18500 – 1/30,000 male births, according to the National Organization for Rare Disease and published peer reviews. The prevalence of DCM is unknown.

On October 25, 2021 Sprint Bioscience reported that it is constantly looking for highly interesting starting points for preclinical drug development projects, primarily in the field of cancer (Press release, Sprint Bioscience, OCT 25, 2021, View Source [SID1234591929]). Through a collaboration with Dr Julian Walfridsson at Karolinska Institutet, the company will identify new target proteins suitable for the treatment of blood cancer. The project has now been rewarded with a 2.5 MSEK research grant from the Swedish Foundation for Strategic Research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 25, 2021, Selecta Biosciences, Inc. (the "Company") reported that it entered into a Sales Agreement (the "Sales Agreement") with SVB Leerink LLC ("SVB Leerink") to sell shares of the Company’s common stock, par value $0.0001 per share (the "Common Stock"), from time to time, through an "at the market" equity offering program under which SVB Leerink will act as sales agent (Filing, 8-K, Selecta Biosciences, OCT 25, 2021, View Source [SID1234591928]). The shares of Common Stock sold pursuant to the Sales Agreement will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-241692), filed on August 6, 2020 with the Securities and Exchange Commission and related prospectus supplement, with respect to up to $75.0 million in sales of Common Stock, filed on October 25, 2021 with the Securities and Exchange Commission.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitations on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, SVB Leerink may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. If expressly authorized by the Company, the SVB Leerink may also sell Common Stock in privately negotiated transactions. The Company will pay SVB Leerink a commission of up to 3.0% of the gross sales proceeds of any shares of Common Stock sold through SVB Leerink under the Sales Agreement, and also has provided SVB Leerink with customary indemnification rights. The offering of shares of Common Stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all shares of Common Stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein.

The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The legal opinion of Covington & Burling LLP relating to the Common Stock being offered pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.